| Literature DB >> 28333978 |
Yang Zhou1, Susan van den Hof2,3, Shengfen Wang1, Yu Pang1, Bing Zhao1, Hui Xia1, Richard Anthony4, Xichao Ou1, Qiang Li1, Yang Zheng1, Yuanyuan Song1, Yanlin Zhao1, Dick van Soolingen4.
Abstract
We describe the population structure of a representative collection of 3,133 Mycobacterium tuberculosis isolates, collected within the framework of a national resistance survey from 2007 in China. Genotyping data indicate that the epidemic strains in China can be divided into seven major complexes, of which 92% belonged to the East Asian (mainly Beijing strains) or the Euro-American lineage. The epidemic Beijing strains in China are closely related to the Beijing B0/W148 strain earlier described in Russia and a large cluster of these strains has spread national wide. The density of Beijing strains is high in the whole of China (average 70%), but the highest prevalence was found North of the Yellow river. The Euro-American lineage consists of three sublineages (sublineage_1, 2, and 3) and is more prevalent in the South. Beijing lineage showed the highest cluster rate of 48% and a significantly higher level of resistance to rifampicin (14%, p<0.001), ethambutol (9%, p = 0.001), and ofloxacin (5%, p = 0.011). Within the Euro-American Lineage, sublineage_3 revealed the highest cluster rate (28%) and presented a significantly elevated level of resistance to streptomycin (44%, p<0.001). Our findings suggest that standardised treatment in this region may have contributed to the successful spread of certain strains: sublineage_3 in the Euro-American lineage may have thrived when streptomycin was used without rifampicin for treatment, while later under DOTS based treatment, in which rifampicin plays a key role, Beijing lineage appears to be spreading.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28333978 PMCID: PMC5363926 DOI: 10.1371/journal.pone.0174197
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Minimum spanning tree based on 24 loci VNTR.
Complexes was defined by difference at 3 or less loci of the 24 VNTR pattern. Lineage name was assigned by comparing to MIRU-VNTRplus database, or by spoligotyping for Manu_ancestor strains.
Fig 2Geographic distribution of the complexes in 31 provinces in mainland of China.
Five most prevalent genotypes with more than 20 strains in each genotype
| MIRU-VNTR genotypes | MIRU-VNTR code | No. of strains in cluster | MLVA code | Clade in spoligotyping |
|---|---|---|---|---|
| VT 007 | 273335444432658253213423 | 133 | 1048–32 | Beijing (133) |
| VT 028 | 273335444432 | 83 | 342–32 | Beijing (82), Manu2(1) |
| VT 111 | 273 | 35 | 204–32 | Beijing (34), T1(1) |
| VT 064 | 273335444432 | 32 | 898–32 | Beijing (32) |
| VT 048 | 27333544443265 | 25 | 100–32 | Beijing (25) |
*Order of VNTR loci: MIRU4, MIRU26, MIRU40, MIRU10, MIRU16, MIRU31, Mtub04, ETRC, ETRA, Mtub30, Mtub39, QUB4156, QUB11b, Mtub21, QUB26, MIRU02, MIRU23, MIRU39, MIRU20, MIRU24, MIRU27, Mtub29, ETRB, Mtub34. The differences between clusters were shown in underlined.
#: MLVA code was given by MIRU-VNTRplus database, which is composed of a digital code for 15 loci VNTR pattern in the front and a digital code for 9 loci VNTR pattern in the end.
Drug resistance per complex.
| Drug | Beijing lineage(n = 2208) | Euro-American sublineage_1 (n = 345) | Euro-American sublineage_2 (n = 225) | Euro-American sublineage_3 (n = 116) | P-value |
|---|---|---|---|---|---|
| number of strains (%, 95%CI) | |||||
| Pan-susceptible | 1389 (62.9,60.9–64.9) | 221 (64.1,58.8–69.1) | 131 (58.2,51.5–64.7) | 56 (48.3,38.9–57.8) | 0.006 |
| Any resistance | |||||
| Isoniazid | 476 (21.6,19.9–23.3) | 61 (17.7,13.8–22.1) | 38 (16.9,12.2–22.4) | 18 (15.5,9.5–23.4) | 0.08 |
| Streptomycin | 602 (27.3,25.4–29.2) | 85 (24.6,20.2–29.5) | 75 (33.3,27.2–39.9) | 51 (44.0,34.8–53.5) | <0.001 |
| Ethambutol | 195 (8.8,7.7–10.1) | 18 (5.2,3.1–8.1) | 11 (4.9,2.5–8.6) | 4 (3.4,0.9–8.6) | 0.007 |
| Rifampicin | 304 (13.8,12.4–15.3) | 32 (9.3,6.4–12.8) | 13 (5.8,3.1–9.7) | 8 (6.9,3.0–13.1) | <0.001 |
| Kanamycin | 45 (2.0,1.5–2.7) | 6 (1.7,0.6–3.7) | 2 (0.9,0.1–3.2) | 5 (4.3,1.4–9.8) | 0.195 |
| Ofloxacin | 107 (4.8,4.0–5.8) | 9 (2.6,1.2–4.9) | 6 (2.7,1.0–5.7) | 0 (0.0,0.0–3.1) | 0.013 |
| MDR | 266 (12.0,10.7–13.5) | 31 (9.0,6.2–12.5) | 10 (4.4,2.2–8.0) | 7 (6.0,2.5–12.0) | <0.001 |
| XDR | 19 (0.9,0.5–1.3) | 1 (0.3,0.0–1.6) | 1 (0.4,0.0–2.5) | 0 (0.0,0.0–3.1) | 0.464 |
* pan-susceptible means susceptible to all six drugs tested; MDR, resistant to at least rifampicin and isoniazid; XDR were also MDR strains and plus resistance to ofloxacin and streptomycin/kanamycin.
# P-value refers to the comparison of the resistance level in each complex and was calculated with Chisq-test or Fisher exact test.
Streptomycin and rifampicin resistance per complex.
| Drug resistance | Beijing lineage (n = 2208) | Euro-American sublineage_1 (n = 345) | Euro-American sublineage_2 (n = 225) | Euro-American sublineage_3 (n = 116) | P-value |
|---|---|---|---|---|---|
| Number of resistant strains(%,95%CI) | |||||
| Susceptible | 1510 (68.4%,68.1–68.7) | 243 (70.4%,69.9–71.1) | 145 (64.4%,64.0–65.2) | 61 (52.6%,51.7–53.4) | <0.001 |
| SM-R/RIF-S- | 394 (17.8%,17.6–18.2) | 70 (20.3%,19.7–20.9) | 67 (29.8%,29.3–30.5) | 47 (40.5%,39.7–41.4) | <0.001 |
| SM-S/RIF-R | 96 (4.3%,4.1–4.7) | 17 (4.9%,4.3–5.6) | 5 (2.2%,1.8–3.0) | 4 (3.4%,2.6–4.3) | 0.411 |
| SM-R/RIF-R | 208 (9.4%,9.1–9.8) | 15 (4.3%,3.8–5.0) | 8 (3.6%,3.1–4.3) | 4 (3.4%,2.6–4.3) | 0.008 |
* susceptible strains were susceptible to both streptomycin (SM) and rifampicin (RIF); SM-R/RIF-S strains were resistant to streptomycin but susceptible to rifampicin; SM-S/RIF-R strains were resistant to rifampicin but susceptible to streptomycin; SM-R/RIF-R strains were resistant to both streptomycin and rifampicin.
# P-value refers to the comparison of the resistance level in each complex and was calculated with Chisq-test or Fisher exact test.
Cluster rate in different genotypes.
| Genotypes | No. of cases | No. of clustered cases | Cluster rate | |
|---|---|---|---|---|
| % | 95% CI | |||
| Beijing lineage | 2208 | 1061 | 48 | 46.0–50.2 |
| Euro-American sublineage_1 | 345 | 65 | 19 | 14.9–23. |
| Euro-American sublineage_2 | 225 | 23 | 10 | 6.6–14.9 |
| Euro-American sublineage_3 | 116 | 33 | 28 | 20.5–37.6 |
| Other complexes | 239 | 21 | 9 | 5.5–13.1 |